Furthermore, Cas9 RNP gene editing and lentiviral transduction were combined to generate PD1 disrupted anti-CD19 CAR T cells which dampened PD/PD-L1 axis and displayed enhanced antitumor activity in vitro and tumor cell lysis in PDL1 + tumor xenografts in myelogenous leukemia murine models, in comparison to normal anti-CD19 CAR T cells [80]. Here, CD19 is linked to myeloid leukemia.